Explore
Validate
LearnV2068
antibody from NSJ Bioreagents
Targeting: CD44
CD44R, CSPG8, HCELL, IN, MC56, MDU2, MDU3, MIC4, Pgp1
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [8]
- Comments [0]
- Validations
- Western blot [2]
- Immunocytochemistry [1]
- Immunohistochemistry [3]
- Other assay [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- V2068 - Provider product page
- Provider
- NSJ Bioreagents
- Product name
- HCAM Antibody CD44
- Antibody type
- Monoclonal
- Antigen
- Stimulated human leukocytes were used as the immunogen for this CD44 / HCAM antibody.
- Description
- Protein G purified antibody
- Reactivity
- Human
- Host
- Mouse
- Conjugate
- Unconjugated
- Antibody clone number
- 156-3C11
- Vial size
- 20 µg, 100 µg (with sodium azide), 100 µg (without sodium azide), 7 ml (prediluted for IHC use, if applicable)
- Storage
- Store the HCAM antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).
Submitted references Overlap of CD44 expression between prostatic small cell carcinoma and acinar adenocarcinoma.
Immunohistochemical expression of CD44 standard and E-cadherin in atypical leiomyoma and leiomyosarcoma of the uterus.
DNA aptamers against exon v10 of CD44 inhibit breast cancer cell migration.
CD44/cellular prion protein interact in multidrug resistant breast cancer cells and correlate with responses to neoadjuvant chemotherapy in breast cancer patients.
T-box transcription factor brachyury is associated with prostate cancer progression and aggressiveness.
Morphological evidences of Bio-Oss® colonization by CD44-positive cells.
Fibromatosis-like metaplastic carcinoma of the breast has a claudin-low immunohistochemical phenotype.
Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers.
Wang CC, De Marzo AM, Lotan TL, Epstein JI
Human pathology 2015 Apr;46(4):554-7
Human pathology 2015 Apr;46(4):554-7
Immunohistochemical expression of CD44 standard and E-cadherin in atypical leiomyoma and leiomyosarcoma of the uterus.
Kaygusuz EI
Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology 2015 Apr;35(3):279-82
Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology 2015 Apr;35(3):279-82
DNA aptamers against exon v10 of CD44 inhibit breast cancer cell migration.
Iida J, Clancy R, Dorchak J, Somiari RI, Somiari S, Cutler ML, Mural RJ, Shriver CD
PloS one 2014;9(2):e88712
PloS one 2014;9(2):e88712
CD44/cellular prion protein interact in multidrug resistant breast cancer cells and correlate with responses to neoadjuvant chemotherapy in breast cancer patients.
Cheng Y, Tao L, Xu J, Li Q, Yu J, Jin Y, Chen Q, Xu Z, Zou Q, Liu X
Molecular carcinogenesis 2014 Sep;53(9):686-97
Molecular carcinogenesis 2014 Sep;53(9):686-97
T-box transcription factor brachyury is associated with prostate cancer progression and aggressiveness.
Pinto F, Pértega-Gomes N, Pereira MS, Vizcaíno JR, Monteiro P, Henrique RM, Baltazar F, Andrade RP, Reis RM
Clinical cancer research : an official journal of the American Association for Cancer Research 2014 Sep 15;20(18):4949-61
Clinical cancer research : an official journal of the American Association for Cancer Research 2014 Sep 15;20(18):4949-61
Morphological evidences of Bio-Oss® colonization by CD44-positive cells.
Galindo-Moreno P, Hernández-Cortés P, Aneiros-Fernández J, Camara M, Mesa F, Wallace S, O'Valle F
Clinical oral implants research 2014 Mar;25(3):366-71
Clinical oral implants research 2014 Mar;25(3):366-71
Fibromatosis-like metaplastic carcinoma of the breast has a claudin-low immunohistochemical phenotype.
Rito M, Schmitt F, Pinto AE, André S
Virchows Archiv : an international journal of pathology 2014 Aug;465(2):185-91
Virchows Archiv : an international journal of pathology 2014 Aug;465(2):185-91
Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers.
Bane A, Viloria-Petit A, Pinnaduwage D, Mulligan AM, O'Malley FP, Andrulis IL
Breast cancer research and treatment 2013 Jul;140(1):195-205
Breast cancer research and treatment 2013 Jul;140(1):195-205
No comments: Submit comment
Supportive validation
- Submitted by
- NSJ Bioreagents (provider)
- Main image
- Experimental details
- Western blot testing of HeLa cell lysate with HCAM antibody (clone 156-3C11). Predicted molecular weight ~81 kDa.
- Submitted by
- NSJ Bioreagents (provider)
- Main image
- Experimental details
- Western blot testing of MDA-MB-231 cell lysate with HCAM antibody (clone 156-3C11). Predicted molecular weight ~81 kDa.
Supportive validation
- Submitted by
- NSJ Bioreagents (provider)
- Main image
- Experimental details
- Immunofluorescent staining of human HeLa cells with HCAM antibody (clone 156-3C11, green) and Reddot nuclear stain (red).
Supportive validation
- Submitted by
- NSJ Bioreagents (provider)
- Main image
- Experimental details
- IHC testing of FFPE human tonsil stained with HCAM antibody (clone 156-3C11).
- Submitted by
- NSJ Bioreagents (provider)
- Main image
- Experimental details
- IHC testing of human breast cancer stained with HCAM antibody (156-3C11).
- Submitted by
- NSJ Bioreagents (provider)
- Main image
- Experimental details
- IHC testing of FFPE human breast cancer stained with HCAM antibody (clone 156-3C11).
Supportive validation
- Submitted by
- NSJ Bioreagents (provider)
- Main image
- Experimental details
- SDS-PAGE Analysis of Purified, BSA-Free HCAM Antibody (clone 156-3C11). Confirmation of Integrity and Purity of the Antibody.
- Submitted by
- NSJ Bioreagents (provider)
- Main image
- Experimental details
- SDS-PAGE analysis of purified, BSA-free HCAM antibody (clone 156-3C11) as confirmation of integrity and purity.
